Neumora Therapeutics, Inc. Common Stock
NMRA
Rank in Stocks
#21554
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company... Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Share Price
$0.3339
Last synced: 2026-11-20
Market Cap
$62.74M
Change (1 day)
-3.78%
Change (1 year)
-85.67%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Neumora Therapeutics, Inc. Common Stock (NMRA)
Category
Healthcare
P/B ratio for Neumora Therapeutics, Inc. Common Stock (NMRA)
P/B ratio as of November 2026 TTM: 1.78
According to Neumora Therapeutics, Inc. Common Stock's latest financial reports and stock price, its current price-to-book ratio (TTM) is 1.78. At the end of 2025 the company had a P/B ratio of 2.82.
P/B ratio history for Neumora Therapeutics, Inc. Common Stock from 2019 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 1.78 | -36.74% |
| 2025 | 2.82 | -52.16% |
| 2024 | 5.89 | 1.94% |
| 2023 | 5.77 | -204.48% |
| 2022 | -5.53 | -27.22% |
| 2021 | -7.59 | -70.98% |
| 2020 | -26.16 | 0.00% |
| 2019 | 0.00 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.5305 | 266.08% |
US
|
|
| 13.101 | 634.40% |
US
|
|
| 4.451 | 149.51% |
AU
|
|
| 4.8339 | 170.97% |
BE
|
|
| 7.2161 | 304.51% |
NL
|
Questions about Neumora Therapeutics, Inc. Common Stock's P/B ratio
What is Neumora Therapeutics, Inc. Common Stock's P/B ratio?
Neumora Therapeutics, Inc. Common Stock's P/B ratio is 1.78, as of Nov 2026.
What was Neumora Therapeutics, Inc. Common Stock's P/B ratio in 2025?
In 2025, Neumora Therapeutics, Inc. Common Stock's P/B ratio was 2.82, compared with 5.89 in 2024.
How has Neumora Therapeutics, Inc. Common Stock's P/B ratio changed since 2020?
From 2020 to 2025, Neumora Therapeutics, Inc. Common Stock's P/B ratio was highest in 2024 (5.89) and lowest in 2020 (-26.16).
How does Neumora Therapeutics, Inc. Common Stock's P/B ratio compare with similar companies?
Neumora Therapeutics, Inc. Common Stock's P/B ratio (1.78) is lower than that of all 5 similar companies listed above. The highest among them is Moderna, Inc., with 13.10.